StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance AKTX opened at $3.61 on Friday. The stock has a market capitalization of $13.44 million, a P/E ratio of -0.52 […]